Elsevier

European Urology

Volume 61, Issue 5, May 2012, Pages e47-e48
European Urology

Letter to the Editor
Reply to Ege Can Serefoglu, Gregory C. Mitchell, and Wayne J.G. Hellstrom’s Letter to the Editor re: Hartmut Porst, Edward D. Kim, Adolfo R. Casabé, et al., for the LVHJ study team. Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled Trial. Eur Urol 2011;60:1105–13

https://doi.org/10.1016/j.eururo.2012.02.017Get rights and content

Section snippets

Conflicts of interest

Hartmut Porst is an investigator, speaker, and consultant for Eli Lilly and Company, Bayer Health-Care, and Pfizer. Edward D. Kim is an investigator, speaker, and consultant for Eli Lilly and Company and a speaker for Watson and Astellas Pharma Inc. Adolfo R. Casabé is an investigator, speaker, and consultant for Eli Lilly and Company, GlaxoSmithKline, Janssen, and Pfizer. Vincenzo Mirone is a consultant, investigator, and speaker for Eli Lilly and Company and Bayer Health-Care. Roberta J.

Cited by (0)

View full text